Hearing status of thalassemic patients treated with dessfroxamin

Majid Ashrafi; Ali Mohammadzadeh

Journal of Kermanshah University of Medical Sciences

Peer-reviewed Medical Quarterly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

Authors Guide Submit Manuscript

Hearing status of thalassemic patients treated with dessfroxamin

Author(s):

Majid Ashrafi^1,*,

Ali Mohammadzadeh²

1Dept. of Audiology, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Dept. of Speech Therapy, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Journal of Kermanshah University of Medical Sciences:Vol. 15, issue 5; e79024

Published online:Jan 19, 2012

Article type:Research Article

Received:Nov 17, 2010

Accepted:Apr 19, 2011

How to Cite:Majid AshrafiAli MohammadzadehHearing status of thalassemic patients treated with dessfroxamin.J Kermanshah Univ Med Sci.15(5):e79024.

Abstract

Background: Major beta thalassemia is the most common inherited anemia with high prevalence in Iran and hearing loss is one of its side effects. The present study aimed to determine the hearing status of patients with major thalassemia and its relationship with serum ferritin level, period of blood transfusion and Dessfroxamin administration.

Methods: This descriptive-analytic study was performed on 80 thalassemia major patients (36 Male and 44 Female) aged 4-32 (14.2 ±2.3) who were referred to Bou Ali Hospital for two years. The studied variables include age, gender, serum ferritin level, amount and duration of Desferal injection and hearing level. All subjects went under evaluation for their otologic and audiometric status. The collected data were analyzed using t-test and ANOVA with SPSS software.

Results: The findings of the study indicated that 38 patients (47%) had entirely hearing loss. Among these 38 patients, 17 patients had sensory neural type f hearing loss 12 patients had conductive and 7 patients had mixed type of hearing problems. The results showed a significant relationship (p<0.05) between hearing loss and serum ferritin level and the dosage and duration of Desferal administration.

Conclusion: Hearing impairment may develop with increasing dosage of Dessfroxamin. Periodic follow up and physical examination is recommended to prevent hearing impairment in major thalassemia.

Keywords

Fulltext

References

1.
The references of this article is available on PDF.

comments